



**FOR IMMEDIATE RELEASE**

**SYNDAX TO PRESENT AT TWO UPCOMING SCIENTIFIC CONFERENCES**

**WALTHAM, Mass., September 16, 2015** – [Syndax Pharmaceuticals, Inc.](#), a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple cancer indications, announced today that the Company's Chief Technology Officer, Peter Ordentlich, Ph.D., will be presenting at two upcoming scientific conferences: [CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: \*Translating Science into Survival\*](#) taking place September 16<sup>th</sup> to 19<sup>th</sup> in New York City, and at the [13<sup>th</sup> Annual Discovery on Target Conference](#) taking place September 21<sup>st</sup> to 24<sup>th</sup> in Boston.

On Wednesday, September 16<sup>th</sup> from 6:45 p.m. to 8:45 p.m. ET, Dr. Ordentlich will be presenting Poster A030: *Epigenetic immune modulation by entinostat in breast cancer: Correlative analysis of ENCORE 301 trial* during Poster Session A: Clinical Trials of Cancer Immunotherapies. The poster summarizes findings from analyses of immune cell subsets from patients treated in Syndax's completed ENCORE 301 clinical trial.

On Monday, September 21<sup>st</sup> at 11:10 a.m. ET during a Symposium entitled "Next Generation Histone Deacetylase Inhibitors, Promising New Chemistries and Biological Strategies for Targeting HDACs," Dr. Ordentlich will present: *Targeting Immunologic and Epigenetic Resistance in Solid Tumors Using HDAC1 Selective Inhibitor Entinostat*, an update of recent scientific advances underlying the entinostat clinical development strategy.

**About Syndax Pharmaceuticals, Inc.**

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma and with Genentech, Inc. for TNBC, as well as a Phase 3 clinical trial with ECOG-ACRIN for advanced hormone receptor positive breast cancer. For more information on Syndax please visit [www.syndax.com](http://www.syndax.com).

###

## **Investor and Media Contacts**

Karen L. Bergman  
BCC Partners  
(650) 575-1509  
kbergman@bccpartners.com

Jen LaVin  
BCC Partners  
(617) 718-0276  
jlavin@bccpartners.com